INTERNATIONAL SEARCH REPORT

inte onal Application No PCT/DK2004/000527

A. CLASSIFICATION OF SUBJECT MATTER
1PC 7 C07K19/00 C07K14/705

A61K38/17 A61K38/43

C07K14/78 A61K38/19 C07K14/52 A61K38/39

C12N9/64

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, Sequence Search, WPI Data, PAJ, BIOSIS

| Category ° | Citation of document, with indication, where appropriate, of t | Relevant to claim No. | | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|--|
| Y | WO 03/016351 A (ENKAM PHARMACE KISELYOV, VLADISLAV, V; SKLADO GALIN) 27 February 2003 (2003- cited in the application the entire document, particula 13-22; page 25, lines 6-26; th | 1-34 | | | | |
| Y | WO 01/16166 A (THE UNITED STAT AMERICA, REPRESENTED BY THE SE DEPARTMENT) 8 March 2001 (2001 pages 2, 13 and 51 (peptide E2 | 1-34 | | | | |
| Y | WO 00/18791 A (STATENS SERUM I HOLM, ARNE; JOERGENSEN, RIKKE, OESTERG) 6 April 2000 (2000-04 cited in the application page 15, line 8 - page 17, lir page 34, line 21 - page 36, li | MALENE; 1-06) ne 20 ne 30 | 1-34 | | | |
| X Furti | her documents are listed in the continuation of box C. | Patent family members are listed | I in annex. | | | |
| "A" docume consider and a docume which citation of docume other in the consider and a docume other in the consideration and a document of the considerat | ent which may throw doubts on priority claim(s) or is cited to establish the publication date of another nor other special reason (as specified) ent referring to an oral disclosure, use, exhibition or | "T" later document published after the in or priority date and not in conflict wit cited to understand the principle or t invention "X" document of particular relevance; the cannot be considered novel or canninvolve an inventive step when the cannot be considered to involve an i document of particular relevance; the cannot be considered to involve an i document is combined with one or n ments, such combination being obvi in the art. | T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled | | | |
| Date of the | actual completion of the international search | Date of mailing of the international se | arch report | | | |
| 3 | May 2005 | 1 0. 06. | 2005 | | | |
| Name and r | nailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nt, | Authorized officer Schmidt, Harald | ···· | | | |

INTERNATIONAL SEARCH REPORT

Inte nal Application No PCT/DK2004/000527

| | | PC1/DK2004/00052/ |
|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| | ation) DOCUMENTS CONSIDERED TO BE RELEVANT | |
| Category ° | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
| A | STAHLHUT M ET AL: "NCAM-FIBRONECTIN-TYPE-III-DOMAIN SUBSTRATA WITH AND WITHOUT A SIX-AMINO-ACID-LONG PROLINE-RICH INSERT INCREASE THE DENDRITIC AND AXONAL ARBORIZATION OF SPINAL MOTONEURONS" JOURNAL OF NEUROSCIENCE RESEARCH, WILEY-LISS, US, vol. 48, 1997, pages 112-121, XP009024260 ISSN: 0360-4012 the whole document | |
| A | KISELYOV VV ET AL.: "Structural Basis for a Direct Interaction between FGFR1 and NCAM and Evidence for a Regulatory Role of ATP" STRUCTURE, vol. 11, June 2003 (2003-06), pages 691-701, XP002319882 cited in the application abstract; figures 6,7 | |
| P,X | WO 2004/056865 A (ENKAM PHARMACEUTICALS A/S; BEREZIN, VLADIMIR; ALBRECHTSEN, MORTEN; BOC) 8 July 2004 (2004-07-08) the whole document | 1-34 |

INTERNATIONAL SEARCH REPORT

International application No. PCT/DK2004/000527

| Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet) |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons: |
| 1. X Claims Nos.: 1-34 (all partially) because they relate to subject matter not required to be searched by this Authority, namely: |
| Although claim 34 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition. |
| 2. Claims Nos.: 1-34 (all partially) because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically: |
| see FURTHER INFORMATION sheet PCT/ISA/210 |
| 3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a). |
| Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet) |
| This International Searching Authority found multiple inventions in this international application, as follows: |
| see additional sheet |
| As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims. |
| 2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee. |
| 3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.: |
| 12,14,17-19 (completely) and 1-11,13,15,16,20-34 (partially) |
| 4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: |
| Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees. |

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.1

Although claim 34 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box II.2

Claims Nos.: 1-34 (all partially)

Present claims 1-10 and 20-34 relate to an extremely large number of possible compounds.

Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Furthermore, it is unclear in the sense of Article 6 PCT what is meant with a sequence of formula L1-A-L2-B-L3-C-L4-D-L5 as defined in claim 1. This expression comprises a wide range of compounds and is therefore speculative, embracing a great variety of possibilities not yet explored by the applicant, the effect of which cannot be expected by the skilled person using the teaching disclosed in the current application and his technical knowledge to reproduce without undue burden all the possibilities which are actually claimed, contrary to Article 5 PCT.

Moreover, the scope of claims 3 and 5-34, in as far as the expressions "(functional) homologues", "fragments", or "variants" are concerned, is so unclear (Article 6 PCT) that a meaningful international search is impossible with regard to these expressions.

Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, and which belong to the first invention, namely those parts relating to the compounds, wherein at least one of the two peptide sequences is a peptide fragment having the amino acid sequence of SEQ ID NO: 1.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

Invention 1: claims 12,17,19 (completely) and 1-11,13,15,16,20-34 (partially)

compound wherein at the least one of the two peptide sequences is a peptide fragment having the amino acid sequence selected from SEQ ID NO: 1, and its use and method

Invention 2: 14,18 (completely) and 1-11,13,15,16,20-34 (partially)

compound wherein at the least one of the two peptide sequences is a peptide fragment having the amino acid sequence selected from SEQ ID NO: 2, and its use and method

Inventions 3-146: 1-11,13,15,16,20-34 (all partially)

compound wherein at the least one of the two peptide sequences is a peptide fragment having the amino acid sequence selected from SEQ ID NOs: 3-146, and its use and method

INTERNATIONAL SEARCH REPORT Inter... mal Application No Information on patent family members PCT/DK2004/000527

| Patent document cited in search report | | Publication date | | Patent family member(s) | | Publication date |
|----------------------------------------|---|------------------|----------------------------------------|-------------------------------------------------------|----------|------------------------------------------------------------------------------------------------|
| WO 03016351 | Α | 27-02-2003 | CA WO EP US | 2457164 03016351 1434798 2004242479 | | 27-02-2003 27-02-2003 07-07-2004 02-12-2004 |
| WO 0116166 | A | 08-03-2001 | AU WO US US | 7078200 0116166 2004092720 6664374 | A2 A1 | 26-03-2001 08-03-2001 13-05-2004 16-12-2003 |
| WO 0018791 | A | 06-04-2000 | AT AU DE DE WO EP US | 6078399 69912827 69912827 0018791 1117677 | | 15-11-2003 17-04-2000 18-12-2003 21-10-2004 06-04-2000 25-07-2001 06-05-2004 |
| WO 2004056865 | Α | 08-07-2004 | AU WO | 2003287918 2004056865 | | 14-07-2004 08-07-2004 |